The society for cardiovascular angiography and interventions structural heart disease early career task force survey results: Endorsed by the society for cardiovascular angiography and interventions

2012 ◽  
Vol 80 (4) ◽  
pp. 706-711 ◽  
Author(s):  
Konstantinos Marmagkiolis ◽  
Abdul Hakeem ◽  
Mehmet Cilingiroglu ◽  
Steven R. Bailey ◽  
Carlos Ruiz ◽  
...  
Keyword(s):  
Heart Disease ◽  
Task Force ◽  
Structural Heart Disease ◽  
Early Career ◽  
Survey Results

Abstract 10906: Heart Failure is Common and Under Recognized in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Nisha A Gilotra ◽  
Abhishek Sawant ◽  
Aditya Bhonsale ◽  
Anneline S te Riele ◽  
Cynthia A James ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Disease ◽  
Right Ventricular ◽  
Structural Changes ◽  
Task Force ◽  
Structural Heart Disease ◽  
Arrhythmogenic Right Ventricular Dysplasia ◽  
Small Subset ◽  
Study Cohort ◽  
Right Ventricular Dysplasia

Introduction: The reported incidence of heart failure (HF) in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) varies depending on study cohort ranging from <10 to 20%. Though risk of fatal arrhythmias is well described, the heterogenous manifestations of HF in this population are less well known. Hypothesis: With more prompt recognition of ARVD/C and subsequent prevention of SCD, HF is becoming more prevalent amongst ARVD/C patients. Methods: Patients from the Johns Hopkins ARVD/C Program Registry meeting the 2010 Revised Task Force Criteria with completed HF symptom survey (n=134) and/or available HF clinical assessment (n=154) were included. HF signs and symptoms were retrospectively adjudicated. Results: Of the 288 patients studied, 236 had evidence of structural heart disease defined as right ventricular (n=199) or biventricular dilatation/dysfunction (n=37). At least one clinical sign or symptom of HF was present in 123 (52%) of those with structural disease (42 had one and 61 had two or more signs/symptoms). The most commonly reported symptoms were dyspnea on exertion (n=87) and fatigue (n=77). Evidence of volume retention (edema or ascites) was found in 46/236 (20%), and left-sided HF symptoms were rare. Of the 105 patients with structural heart disease and known age at HF symptom onset, average time from first ARVD/C presentation to HF symptoms was 6.3 ± 8.0 years, and 40% had at least one episode of sustained ventricular tachycardia or ICD shock prior to HF symptoms. Presence of a genetic mutation for ARVD/C did not correlate with HF symptoms or structural changes. Sixteen patients underwent orthotopic heart transplant. Conclusions: HF symptoms are common in the ARVD/C population with structural heart disease. Though there is a small subset of patients with evident volume overload requiring therapy, there is a larger portion of patients with HF symptoms that may be under recognized.

Pearls for a Successful Early Career in Structural Heart Disease Interventions

2018 ◽  
Vol 2 (4) ◽  
pp. 281-285
Author(s):  
Abdul Moiz Hafiz ◽  
Nikolaos Kakouros ◽  
Marie-France Poulin
Keyword(s):  
Heart Disease ◽  
Structural Heart Disease ◽  
Early Career

Identification of High-risk Patients for Implantable Cardioverter–Defibrillator Therapy in Asia

2011 ◽  
Vol 3 (1) ◽  
pp. 77
Author(s):  
Cyril YK Ko ◽  
Jeffrey WH Fung ◽  
◽  
Keyword(s):  
Heart Disease ◽  
Implantable Cardioverter Defibrillator ◽  
Asian Population ◽  
Structural Heart Disease ◽  
Medical Problem ◽  
Western World ◽  
Asian Countries ◽  
Cardioverter Defibrillator ◽  
Asian Patients ◽  
Risk Patients

Sudden cardiac death (SCD) is a serious medical problem worldwide. Multiple landmark studies have demonstrated the benefit of implantable cardioverter–defibrillator (ICD) therapy in preventing SCD in at-risk patients. Although the data available in Asia are limited, the disease pattern seems to be different from that in the western world. The Asian population seems to have a lower incidence of SCD. Coronary heart disease, which is the major underlying cause of SCD in the west, may play a less important role in Asian countries. In addition, non-structural heart disease seems to be a more prevalent cause of SCD in Asia. It is thus questionable whether the results of ICD trials can be applied directly to Asian countries, as most of these trials seldom recruited Asian patients. This article will review SCD in Asia, focusing on the epidemiology and risk factors for SCD in Asia and highlighting some unique features that may be different from those seen in the western world.

Sign in / Sign up

Export Citation Format

Share Document